Lazard Asset Management
CTMX icon

Lazard Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Lazard Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,316
Closed -$98K – 1921
2025
Q2 		$98K Buy
43,316
+42,500
+5,208% +$68.5K ﹤0.01% 1869
2025
Q1 		$0 Sell
816
-4,689
-85% -$3.64K ﹤0.01% 2350
2024
Q4 		$5K Sell
5,505
-3,323
-38% -$3.58K ﹤0.01% 2129
2024
Q3 		$10K Sell
8,828
-9,653
-52% -$12.3K ﹤0.01% 2030
2024
Q2 		$22K Buy
18,481
+17,263
+1,417% +$34.4K ﹤0.01% 2012
2024
Q1 		$2K Sell
1,218
-33
-3% -$61 ﹤0.01% 1935
2023
Q4 		$1K Buy
+1,251
New +$1.65K ﹤0.01% 2193
2022
Q3 		– Sell
-15,186
Closed -$27K – 2357
2022
Q2 		$27K Hold
15,186
– – ﹤0.01% 2043
2022
Q1 		$40K Buy
+15,186
New +$58.3K ﹤0.01% 1844
2021
Q1 		– Sell
-8,292
Closed -$54K – 1878
2020
Q4 		$54K Buy
+8,292
New +$59.2K ﹤0.01% 1360
2020
Q3 		– Sell
-963
Closed -$8K – 1625
2020
Q2 		$8K Sell
963
-48,637
-98% -$452K ﹤0.01% 1504
2020
Q1 		$380K Hold
49,600
– – ﹤0.01% 830
2019
Q4 		$412K Sell
49,600
-1,600
-3% -$10.8K ﹤0.01% 828
2019
Q3 		$377K Hold
51,200
– – ﹤0.01% 852
2019
Q2 		$574K Hold
51,200
– – ﹤0.01% 922
2019
Q1 		$550K Buy
51,200
+12,000
+31% +$177K ﹤0.01% 905
2018
Q4 		$591K Hold
39,200
– – ﹤0.01% 780
2018
Q3 		$725K Buy
+39,200
New +$893K ﹤0.01% 787

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Lazard Asset Management's CTMX Position: Q3 2025 in Review

Lazard Asset Management sold out of CytomX Therapeutics (CTMX) in Q3 2025, closing a stake of 43,316 shares — an estimated $98K sold.

Lazard Asset Management first reported a position in CTMX in Q3 2018 and held it in 18 quarters. The position peaked at $725K in Q3 2018. 103 funds tracked by Wall St. Rank hold CTMX as of Q3 2025.

  • Lazard Asset Management reported no remaining CytomX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 43,316 CytomX Therapeutics shares in Q3 2025, an estimated $98K.
  • Lazard Asset Management first reported a position in CytomX Therapeutics in Q3 2018 and held it in 18 quarters.
  • Lazard Asset Management's CytomX Therapeutics position peaked at $725K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.